PMID- 21135860
OWN - NLM
STAT- MEDLINE
DCOM- 20110513
LR  - 20130304
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 25
IP  - 3
DP  - 2011 Mar
TI  - Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts 
      early relapse in AML and MDS patients after hematopoietic cell transplantation 
      with reduced-intensity conditioning.
PG  - 498-505
LID - 10.1038/leu.2010.283 [doi]
AB  - Relapse of malignant disease remains the major complication in patients with 
      acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after 
      hematopoietic cell transplantation (HCT) with reduced-intensity conditioning 
      (RIC). In this study, we investigated the predictive value of disease-specific 
      markers (DSMs), donor chimerism (DC) analysis of unsorted (UDC) or CD34(+) sorted 
      cells and Wilms' tumor gene 1 (WT1) expression. Eighty-eight patients with AML or 
      MDS were monitored after allogenic HCT following 2 Gy total-body irradiation with 
      (n=84) or without (n=4) fludarabine 3 x 30 mg/m(2), followed by cyclosporin A and 
      mycophenolate mofetil. DSMs were determined by fluorescence in situ hybridization 
      (FISH) and WT1 expression by real-time polymerase chain reaction. Chimerism 
      analysis was performed on unsorted or CD34(+) sorted cells, by FISH or short 
      tandem repeat polymerase chain reaction. Twenty-one (24%) patients relapsed 
      within 4 months after HCT. UDC, CD34(+) DC and WT1 expression were each 
      significant predictors of relapse with sensitivities ranging from 53 to 79% and 
      specificities of 82-91%. Relapse within 28 days was excluded almost entirely on 
      the basis of WT1 expression combined with CD34(+) DC kinetics. Monitoring of WT1 
      expression and CD34(+) DC predict relapse of AML and MDS after RIC-HCT.
FAU - Lange, T
AU  - Lange T
AD  - Department of Hematology, Oncology and Hemostaseology, University of Leipzig, 
      Leipzig, Germany. langet@medizin.uni-leipzig.de
FAU - Hubmann, M
AU  - Hubmann M
FAU - Burkhardt, R
AU  - Burkhardt R
FAU - Franke, G-N
AU  - Franke GN
FAU - Cross, M
AU  - Cross M
FAU - Scholz, M
AU  - Scholz M
FAU - Leiblein, S
AU  - Leiblein S
FAU - Al-Ali, H K
AU  - Al-Ali HK
FAU - Edelmann, J
AU  - Edelmann J
FAU - Thiery, J
AU  - Thiery J
FAU - Niederwieser, D
AU  - Niederwieser D
LA  - eng
PT  - Journal Article
DEP - 20101207
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antigens, CD34)
SB  - IM
CIN - Expert Rev Mol Diagn. 2011 May;11(4):361-6. PMID: 21545254
MH  - Adult
MH  - Aged
MH  - Antigens, CD34/*analysis
MH  - Blood Donors
MH  - Disease-Free Survival
MH  - Female
MH  - *Genes, Wilms Tumor
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid, Acute/*genetics/mortality/therapy
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*genetics/mortality/therapy
MH  - Recurrence
MH  - Transplantation Chimera
MH  - *Transplantation Conditioning
EDAT- 2010/12/08 06:00
MHDA- 2011/05/14 06:00
CRDT- 2010/12/08 06:00
PHST- 2010/12/08 06:00 [entrez]
PHST- 2010/12/08 06:00 [pubmed]
PHST- 2011/05/14 06:00 [medline]
AID - leu2010283 [pii]
AID - 10.1038/leu.2010.283 [doi]
PST - ppublish
SO  - Leukemia. 2011 Mar;25(3):498-505. doi: 10.1038/leu.2010.283. Epub 2010 Dec 7.